Prestige Consumer Healthcare Inc. $PBH Shares Sold by Clearbridge Investments LLC

Clearbridge Investments LLC trimmed its stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 8.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 116,490 shares of the company’s stock after selling 10,220 shares during the quarter. Clearbridge Investments LLC’s holdings in Prestige Consumer Healthcare were worth $7,186,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Bayforest Capital Ltd bought a new stake in shares of Prestige Consumer Healthcare during the 4th quarter worth about $29,000. Barrow Hanley Mewhinney & Strauss LLC raised its position in shares of Prestige Consumer Healthcare by 106.8% during the 3rd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 548 shares of the company’s stock worth $34,000 after buying an additional 283 shares in the last quarter. Torren Management LLC bought a new stake in shares of Prestige Consumer Healthcare during the 4th quarter worth about $35,000. Danske Bank A S bought a new stake in shares of Prestige Consumer Healthcare during the 3rd quarter worth about $37,000. Finally, Hantz Financial Services Inc. lifted its position in Prestige Consumer Healthcare by 373.6% in the third quarter. Hantz Financial Services Inc. now owns 682 shares of the company’s stock worth $43,000 after purchasing an additional 538 shares during the period. 99.95% of the stock is currently owned by institutional investors.

Prestige Consumer Healthcare Stock Performance

Shares of NYSE PBH opened at $49.09 on Thursday. The company has a quick ratio of 2.25, a current ratio of 3.57 and a debt-to-equity ratio of 0.54. The stock has a market capitalization of $2.33 billion, a price-to-earnings ratio of 12.55, a PEG ratio of 1.56 and a beta of 0.35. The stock’s fifty day simple moving average is $52.42 and its 200 day simple moving average is $59.75. Prestige Consumer Healthcare Inc. has a 52-week low of $42.62 and a 52-week high of $87.12.

Prestige Consumer Healthcare (NYSE:PBH) last issued its earnings results on Wednesday, May 13th. The company reported $1.23 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.39 by ($0.16). The company had revenue of $281.62 million during the quarter, compared to analyst estimates of $293.64 million. Prestige Consumer Healthcare had a return on equity of 11.54% and a net margin of 17.48%.The business’s revenue was down 5.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.32 earnings per share. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. As a group, sell-side analysts forecast that Prestige Consumer Healthcare Inc. will post 4.45 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 1,207 shares of the company’s stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $54.99, for a total transaction of $66,372.93. Following the completion of the sale, the vice president directly owned 42,820 shares of the company’s stock, valued at approximately $2,354,671.80. This represents a 2.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 1.40% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on PBH. Weiss Ratings downgraded Prestige Consumer Healthcare from a “hold (c)” rating to a “hold (c-)” rating in a research report on Thursday, May 14th. Canaccord Genuity Group cut their target price on Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Oppenheimer downgraded Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 14th. Finally, Zacks Research downgraded Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research report on Monday, May 18th. Two research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Prestige Consumer Healthcare has an average rating of “Hold” and a consensus price target of $70.75.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).